File photo shows a staff member displays samples of the COVID-19 inactivated vaccine at Sinovac Biotech Ltd., in Beijing. (Xinhua File/Zhang Yuwei)
A phase 2 trial of a COVID-19 vaccine candidate in China has found that the vaccine is safe and induces an immune response, according to a new study published Monday in medical journal The Lancet.
版權及免責聲明:凡本網所屬版權作品,轉載時須獲得授權并注明來源“粵港澳頭條”,違者本網將保留追究其相關法律責任的權力。凡轉載文章,不代表本網觀點和立場。
版權所有:粵港澳頭條 技術支持:友點軟件